NanoPac (paclitaxel nanoformulation)

P2, N=54, Completed, NanOlogy, LLC | Phase classification: P2a --> P2

Increases in natural killer (NK) cells were found in lymph node tissue in the combination treatment group. These findings suggest that IT LSAM-PTX may provide benefit in the local treatment of melanomas and may synergize with systemic anti-PD-1 therapy, leading to additional tumoricidal outcomes without added systemic toxicity.

P2, N=18, Completed, NanOlogy, LLC | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Sep 2023

P2a, N=54, Completed, NanOlogy, LLC | Active, not recruiting --> Completed

P2, N=30, Active, not recruiting, NanOlogy, LLC | Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020

miRNA delivery to a specific target site, the development of paclitaxel and miRNA formulations, and nanotechnological strategies for the delivery of nanopaclitaxel in the management of breast cancer are discussed...An in silico analysis revealed that ANG1005 and Abraxane nanoformulations have superior and significantly enhanced interactions with the proteins α-tubulin and Bcl-2...miRNAs can revert abnormal gene expression to normalcy; since miRNAs serve as tumor suppressors. Therefore, restoration of particular miRNAs levels as a replacement therapy may be an effective endocrine potential strategy for treating ER positive/ negative breast cancers.